Cycled Phototherapy Dose-Finding Study for Extremely Low-Birth-Weight Infants: A Randomized Clinical Trial.
Journal
JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
pubmed:
28
4
2020
medline:
23
3
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Cycled (intermittent) phototherapy (PT) might adequately control peak total serum bilirubin (TSB) level and avoid mortality associated with usual care (continuous PT) among extremely low-birth-weight (ELBW) infants (401-1000 g). To identify a cycled PT regimen that substantially reduces PT exposure, with an increase in mean peak TSB level lower than 1.5 mg/dL in ELBW infants. This dose-finding randomized clinical trial of cycled PT vs continuous PT among 305 ELBW infants in 6 US newborn intensive care units was conducted from March 12, 2014, to November 14, 2018. Two cycled PT regimens (≥15 min/h and ≥30 min/h) were provided using a simple, commercially available timer to titrate PT minutes per hour against TSB level. The comparator arm was usual care (continuous PT). Mean peak TSB level and total PT hours through day 14 in all 6 centers and predischarge brainstem auditory-evoked response wave V latency in 1 center. Mortality and major morbidities were secondary outcomes despite limited power. Consent was requested for 452 eligible infants and obtained for 305 (all enrolled) (mean [SD] birth weight, 749 [152] g; gestational age, 25.7 [1.9] weeks; 81 infants [27%] were multiple births; 137 infants [45%] were male; 112 [37%] were black infants; and 107 [35%] were Hispanic infants). Clinical and demographic characteristics of the groups were similar at baseline. After a preplanned interim analysis of 100 infants, the regimen of 30 min/h or more was discontinued, and the study proceeded with 2 arms. Comparing 128 infants receiving PT of 15 min/h or more with 128 infants receiving continuous PT among those surviving to 14 days, mean peak TSB levels were 7.1 vs 6.4 mg/dL (adjusted difference, 0.7; 95% CI, 0.4-1.1 mg/dL) and mean total PT hours were 34 vs 72 (adjusted difference, -39; 95% CI, -45 to -32). Wave V latency adjusted for postmenstrual age was similar in 37 infants receiving 15 min/h or more of PT and 33 infants receiving continuous PT: 7.42 vs 7.32 milliseconds (difference, 0.10; 95% CI, -0.11 to 0.30 millisecond). The relative risk for death was 0.79 (95% CI, 0.40-1.54), with a risk difference of -4.5% (95% CI, -10.9 to 2.0). Morbidities did not differ between groups. Cycled PT can substantially reduce total PT with little increase in peak TSB level. A large, randomized trial is needed to assess whether cycled PT would increase survival and survival without impairment in small, preterm infants. ClinicalTrials.gov Identifier: NCT01944696.
Identifiants
pubmed: 32338720
pii: 2765039
doi: 10.1001/jamapediatrics.2020.0559
pmc: PMC7186919
doi:
Substances chimiques
Biomarkers
0
Bilirubin
RFM9X3LJ49
Banques de données
ClinicalTrials.gov
['NCT01944696']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-656Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001439
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR003168
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001105
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001120
Pays : United States
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Références
Biol Neonate. 1989;56(4):204-9
pubmed: 2529913
Electroencephalogr Clin Neurophysiol. 1984 Sep;59(5):411-9
pubmed: 6205868
Mol Cell Biochem. 2008 Oct;317(1-2):51-9
pubmed: 18560765
Acta Paediatr. 1998 Jul;87(7):786-91
pubmed: 9722254
Stat Med. 2012 Nov 10;31(25):2955-72
pubmed: 22711340
Pediatrics. 2016 Jun;137(6):
pubmed: 27217478
N Engl J Med. 2008 Oct 30;359(18):1885-96
pubmed: 18971491
Evid Based Med. 2017 Mar;22(1):39-40
pubmed: 27849162
BMJ. 1999 Aug 21;319(7208):508-12
pubmed: 10454409
Semin Perinatol. 2014 Nov;38(7):452-64
pubmed: 25308614
Mutat Res. 2009 May 31;676(1-2):17-20
pubmed: 19376266
J Pediatr. 1994 Feb;124(2):309-12
pubmed: 8301444
Arch Dis Child. 1984 Sep;59(9):892-4
pubmed: 6486869
Clin Perinatol. 2016 Jun;43(2):291-5
pubmed: 27235208
J Perinatol. 2016 Feb;36(2):132-6
pubmed: 26583945
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Trends Mol Med. 2016 Sep;22(9):758-768
pubmed: 27515064
Clin Perinatol. 2016 Jun;43(2):259-76
pubmed: 27235206
Lancet. 1958 May 24;1(7030):1094-7
pubmed: 13550936
Pediatr Res. 2012 Jan;71(1):77-84
pubmed: 22289854
J Perinatol. 2012 Sep;32(9):677-84
pubmed: 22652561
J Clin Epidemiol. 2009 Jan;62(1):13-21.e5
pubmed: 18947971
Semin Perinatol. 2004 Oct;28(5):326-33
pubmed: 15686263
Clin Perinatol. 2016 Jun;43(2):241-57
pubmed: 27235205
JAMA. 2018 Dec 4;320(21):2208-2210
pubmed: 30347047
JAMA. 2017 Oct 24;318(16):1550-1560
pubmed: 29067428
Pediatrics. 2018 Oct;142(4):
pubmed: 30249623
J Perinatol. 2013 Feb;33(2):126-33
pubmed: 22499082
Semin Perinatol. 2011 Jun;35(3):162-70
pubmed: 21641490
Pediatrics. 2000 Feb;105(2):350-3
pubmed: 10654954
Epilepsy Res. 2016 Aug;124:67-72
pubmed: 27259071
Mutat Res. 2009 Nov-Dec;680(1-2):12-6
pubmed: 19712750
Eur J Pediatr. 2015 Feb;174(2):177-81
pubmed: 25005717
Semin Perinatol. 2014 Nov;38(7):397-406
pubmed: 25267279
Pediatr Neurol. 1986 May-Jun;2(3):127-32
pubmed: 3508686
Eur J Pediatr. 2015 Apr;174(4):459-64
pubmed: 25209224
J Pediatr. 1978 Apr;92(4):627-30
pubmed: 633026
Pediatrics. 2003 Oct;112(4):773-9
pubmed: 14523165
J Perinatol. 1999 Jun;19(4):271-4
pubmed: 10685237
Pediatrics. 1991 Jun;87(6):797-805
pubmed: 2034482
Neonatology. 2009;95(3):262-6
pubmed: 19005263
BMJ. 1995 Dec 16;311(7020):1621-5
pubmed: 8555809
Pediatrics. 2016 Jun;137(6):
pubmed: 27217477
J Pediatr. 1982 Apr;100(4):624-6
pubmed: 7062214
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753